Therapy-induced APOBEC3A drives evolution of persistent cancer cells
Hideko Isozaki, Ramin Sakhtemani, Ammal Abbasi, Naveed Nikpour, Marcello Stanzione, Sunwoo Oh, Adam Langenbucher, Susanna Monroe, Wenjia Su, Heidie Frisco Cabanos, Faria M. Siddiqui, Nicole Phan, Pégah Jalili, Daria Timonina, Samantha Bilton, María Gomez‐Caraballo, Hannah L. Archibald, Varuna Nangia, Kristin Dionne, Amanda K. Riley, Matthew A. Lawlor, Mandeep K. Banwait, Rosemary Cobb, Lee Zou, Nicholas J. Dyson, Christopher J. Ott, Cyril H. Benes, Gad Getz, Chang S. Chan, Alice T. Shaw, Justin F. Gainor, Jessica J. Lin, Lecia V. Sequist, Zofia Piotrowska, Beow Y. Yeap, Jeffrey A. Engelman, Jake June-Koo Lee, Yosef E. Maruvka, Rémi Buisson, Michael S. Lawrence, Aaron N. Hata
Topics & Concepts
APOBECCytidine deaminaseDrug resistanceTargeted therapyCancer researchGenome instabilityCancerBiologyCytidineMedicineGeneticsDNA damageDNAGeneGenomeEnzymeBiochemistryCRISPR and Genetic EngineeringRNA modifications and cancerRNA and protein synthesis mechanisms